Taro shareholders approved merger with Sun Pharma
The merger was approved at meetings on May 22, 2024, and is expected to close in about 35 days, pending conditions.
See the latest news and media coverage for Taro. We track all announcements, press releases, and industry mentions in real time, all in one place.
Generic pharmaceutical and consumer healthcare company
taro.comLast updated
In short: Taro merged with Sun Pharma and faced recalls, lawsuits, and new generic product launches.
The merger was approved at meetings on May 22, 2024, and is expected to close in about 35 days, pending conditions.
Sun Pharma will acquire all outstanding Taro shares for US$43.00 per share in cash.
The generic lansoprazole delayed-release capsules are approved by the FDA.
This approval allows Taro to market a generic alternative to Depo-Testosterone Injection.
NEW DELHI (dpa-AFX) - Sun Pharmaceutical Industries Ltd. (SUNPHARMA), a pharmaceutical company, on Thursday announced the commercial availability of Taro-Methylphenidate ER for patients in Ontario...
Sun Pharma's subsidiaries have reached a settlement with a plaintiff in the US generic pharmaceuticals pricing antitrust litigation for a confidential amount. The agreement provides...
The Taro stock has disappeared from the exchange at $32.25 per share following a cash takeover. The pharmaceutical company, which focuses on dermatology, is being fully integrated, while...
Taro Pharmaceutical Industries (Hawthorne, NY) announced that its Board of Directors has appointed Mr. Abhay Gandhi to the position of Interim Chief Executive Officer, effective...
Track Taro and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Taro and other trending companies.